Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For SNAP-CAR T And SNAP-CAR NK

Author: Benzinga Newsdesk | February 26, 2024 10:02am

Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications.

Posted In: COEP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist